

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 694 305 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
28.02.2001 Bulletin 2001/09

(51) Int Cl.7: **A61K 35/78**, A61K 31/37,
A61K 31/35

(21) Application number: **95111054.3**

(22) Date of filing: **14.07.1995**

(54) **Pharmaceutical or cosmetic formulations containing coumarins and proanthocyanidins**

Pharmazeutische oder kosmetische Zusammensetzungen, welche Coumarine und Proanthocyanidine
enthalten

Formulations pharmaceutiques ou cosmétiques contenant des coumarines et des proanthocyanidines

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **26.07.1994 IT MI941590**

(43) Date of publication of application:
31.01.1996 Bulletin 1996/05

(73) Proprietor: **INDENA S.p.A.**
20141 Milano (IT)

(72) Inventors:
• **Bombardelli, Ezio**
I-20141 Milano (IT)
• **Cristoni, Aldo**
I-20141 Milano (IT)
• **Morazzoni, Paolo**
I-20141 Milano (IT)

(74) Representative: **Blanchetti, Giuseppe, Prof.**
Blanchetti Bracco Minoja S.r.l.
Via Rossini, 8
20122 Milano (IT)

(56) References cited:
EP-A- 0 275 224 EP-A- 0 348 781
EP-A- 0 412 300 GB-A- 1 589 294

• **PHLEBOLOGIE (GERMANY), 1994, 23/3 (71-77),**
GERMANY, HOSTETTMANN K. ET AL 'ZU
INHALTSSTOFFEN UND PHARMAKOLOGIE
PFLANZLICHER VENENMITTEL'

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 694 305 B1

Description

[0001] The present invention relates to the use of novel formulations for the topical use containing combinations of coumarins, such as esculoside, esculetin, extracts containing them or mixtures thereof, with dimeric and oligomeric proanthocyanidins for the treatment of peripheral vasculopathies related to an impaired peripheral microcirculation; moreover, the invention relates to the use of said coumarin derivatives in combination with proanthocyanidins in the cicatrization processes and in the complications of chronic venous stasis (leg heaviness, ulcus cruris) and in the treatment of internal and external hemorrhoids. In a strictly cosmetic field, the combinations are used in the treatment of unesthetisms related to superficial capillaries (couperose), rosacea, telangiectasias and the like. It has surprisingly been found that a strong synergism exists between these coumarin derivatives and proanthocyanidins.

[0002] The microvasculokinetic activity of esculoside, responsible for many of the properties of the combinations (cicatrizing and antihemorrhoid) was evaluated by non-invasive techniques such as infrared photopulsoplethysmography, Laser-Doppler and video-capillaroscopy which allows to check the districtual microangiotectionic and the capillary morphological changes before and after the treatment with the tested substances. Esculoside induces favourable changes in the capillary density, up to 300% higher than the basal values.

[0003] In the combinations according to the invention, the weight ratio of coumarin derivatives to proanthocyanidins preferably ranges from 4:1 to 1:4. For example, combinations of three parts of esculoside and one part of proanthocyanidins (selected from proanthocyanidin A2 and the procyanidole oligomers of a different origin, preferably those extracted from Vitis vinifera or Camellia sinensis) exert synergistic activities which are qualitatively different from those of the single components; a non-limiting interpretation of this fact is that esculoside increases the proanthocyanidin absorption at the topical level as a consequence of the increase in districtual blood flow, and therefore of water. Particularly synergistic is the modulating activity on the cicatrization process, wherein a stimulation of the tissue restoration and a regular orientation alongside the cicatricial axis are observed, thus preventing the formation of keloids.

[0004] Analogously, these combinations are favourably used in the unesthetisms and on the reduction of the couperose. In the latter case, 20 individuals of both sexes were treated on one side of the face in the temporal-zygomatic area with a 1.5% esculoside and 0.5% of proanthocyanidin A2 formulation and on the other side with placebo. The treatment continued for 60 days twice a day; the evaluation of the intensity of the unesthetism was performed by means of scores and with objective evaluations measuring the colour intensity of the area treated with the combination of the invention compared with that treated with placebo. After the treatment, a 41% reduction in the unesthetism was observed, using the patient himself as control.

[0005] Particularly important is the healing effect of the combinations according to the invention, which effect can be used in plastic surgery as well as in decubitus and venous stasis ulcers. To evaluate the cicatrization effect, patients were selected which had undergone superficial surgery, having wounds of a size suitable to the simultaneous treatment with the combination of the invention and with placebo. For example: cauterized wounds larger than 2 cm, so as to allow, after suture, the treatment of 1 cm with a placebo formulation and of 1 cm with a formulation containing 1.5% esculoside and 1.5% procyanidole oligomers from Vitis vinifera. Immediately after the treatment, the adhesion edges and nearby areas of the wound were checked with a videocapillaroscope (Scopeman-Moritex Video Imaging System, Alpha Strumenti, Milan), fitted with a halogen-light optical probe with 50 to 400 x magnifications, measuring the capillary density (number of blood-perfused capillaries per area unit) and evaluating the space orientation of the capillaries and their morphology. 15 Minutes after the treatment, the capillary density increased by 100% compared with the basal one and with the placebo-treated control. Surprisingly it has been found, and it is a part of the present invention, that following the improved districtual circulation (the cicatricial area is usually poorly vascularized, contrary to what was believed up to now) and the fibroblast proliferation stimulation, a remarkable induction of a regular capillarogenesis takes place. The wound healing with the products of the present invention turned out to be accelerated and at the same time modulated. In bedsores and torpid ulcers, the larger blood flow to the necrotic area leads to a restoration of the tissue healing properties and a reduction and disappearance of the ulcer. Analogous results are obtained in the hemorrhoidal pathology, in which the simultaneous effect on arteries and veins allows a fast regression of venous stasis.

[0006] The treatment above described relates to the treatment of cauterized wounds and or healing wounds, or of cutaneous ulcers, or of venous stasis conditions. Further, it has surprisingly been found that the administration of a formulation containing 1% esculetin and 0.3% procyanidanole oligomers from Camellia sinensis on newly formed scars leads to a faster disappearance of the cicatricial outcome, with a remarkable reduction in the hyperhaemic area compared with the controls. The result of such a treatment is particularly important in the exposed body areas, where facial esthetic surgery, removal of naevi and the like are performed.

[0007] Moreover, it has been found that the above cited coumarins, alone or in combination with proanthocyanidins, are markedly effective in the treatment of atopic dermatitis and haematomas of any origin. Therefore, topical administrations of a formulation containing 2% esculetin on atopic dermatitis induce a reduction of the dermatitis within one week or in even shorter times, depending on the severity and degree of the pathology. The same formulation, applied on haematomas, made them to disappear within a few days, probably thanks to the microvasculokinetic activity of the

product.

[0008] Particularly useful as excipients for the formulations of the invention proved to be phospholipids, pure or in form of the natural mixtures thereof, which allow a quick absorption of the substances themselves, even though other excipients can advantageously carry the products of the invention, enhancing their therapeutical or dermocosmetic functionalities.

[0009] The formulations according to the invention contain, besides the above defined active principles, carriers, additives, preservatives and the like known in pharmaceutical technique, such as those listed in the examples reported hereinbelow.

Example I - Gel containing esculoside and procyanidole oligomers from *Vitis vinifera*. 100 g of gel contain:

Esculoside	1.50 g
96% Procyanidole oligomers	1.50 g
Hydrogenated castor oil 40(OE) (Cremophor RH40 - BASF)	1.00 g
Propylene glycol	1.50 g
Preservatives	0.10 g
Hydroxyethyl cellulose (Natrosol 250 HHX - Aqualon)	3.00 g
Purified water	q.b. a 100 g

Example II - Alcoholic fluid gel containing esculoside and proanthocyanidin A2. 100 g of gel contain:

Esculoside	1.50 g
Proanthocyanidin A2	0.50 g
Hydrogenated castor oil 40(OE) (Cremophor RH40 - BASF)	5.00 g
Propylene glycol	3.00 g
Carbomer 940 (Carbopol 980 - Goodrich)	1.00 g
Ethanol 95°	45.00 g
Phosphatidylcholine (Phospholipon 90- Natterman)	1.60 g
Glycerol 6(OE) Caprilate/Caprylate (Softigen 767)	15.00 g
Preservatives	0.40 g
Butylhydroxytoluene	0.05 g
α -Tocopherol	0.20 g
Ascorbic acid	0.30 g
Dimethicone copolyol (SF 1188 - General Electric)	2.00 g
10% Triethanolamine	5.00 g
Purified water	q.s. to 100 g

Example III - Cream containing esculoside and proanthocyanidin A2. 100 g of cream contain:

Esculoside	2.50 g
Proanthocyanidin A2	
Hydrogenated castor oil 40(OE)	1.00 g
(Cremophor RH40 - BASF)	2.00 g
Propylene glycol	2.00 g
Carbomer 934 (Carbopol 934 P - Goodrich)	0.50 g
Alkyl C ₁₀₋₃₀ -Acrylate (Carbopol 1382 - Goodrich)	0.50 g
Ethanol 95°	15.00 g
Preservatives	0.40 g
Cetyl Palmitate	
(Cutina CP - Henkel)	8.00 g
Polyisoprene (Syntesqual - Vevy)	5.00 g
Polysorbate 80 (Tween 80 - ICI Americans)	2.00 g
α -Tocopherol	0.20 g

(continued)

Example III - Cream containing esculoside and proanthocyanidin A2. 100 g of cream contain:

Ascorbyl palmitate	0.10 g
Hydrogenated lanolin (Lanocera - Esperis)	5.00 g
Dimethicone 350 cps (Tegiloxan 350 - Tego)	0.50 g
Phosphatidylcholine (Phospholipon 90- Natterman)	2.50 g
10% NaOH sol.	2.40 g
Purified water	q.s. to 100 g

Example IV - Gelified emulsion containing esculetin and procyanidole oligomers from Camellia sinensis. 100 g of emulsion contain:

Esculetin	1.00 g
96% Procyanidole oligomers	0.30 g
Isopropyl myristate	5.00 g
Preservatives	0.40 g
Perfume	0.10 g
Polyacrylamide, C ₁₃₋₁₄ -isoparaffin and lauric alcohol 7(OE) (Sepigel 305 - Seppic)	3.00 g
Purified water	q.s. to 100 g

Example V (comparative) - Gelified emulsion containing esculetin. 100 g of gelified emulsion contain:

Esculetin	2.00 g
Isopropyl myristate	5.00 g
Preservatives	0.40 g
Perfume	0.10 g
Polyacrylamide, C ₁₃₋₁₄ -isoparaffin and lauric alcohol 7(OE) (Sepigel 305 - Seppic)	3.00 g
Purified water	q.s. to 100 g

Claims

1. Pharmaceutical and/or cosmetic formulations for topical use, containing as active principles:

a) coumarins selected from esculoside, esculetin, extracts containing them and mixtures thereof, combined with
b) dimeric and oligomeric proanthocyanidins.

2. Pharmaceutical and/or cosmetic formulations according to claim 1, characterized in that the contained proanthocyanidins are selected from the group consisting of proanthocyanidin A2, procyanidole oligomers extracted from Vitis vinifera and Camellia sinensis, and mixtures thereof.

3. Pharmaceutical and/or cosmetic formulations according to claim 2, characterized in that the contained proanthocyanidin is proanthocyanidin A2.

4. Pharmaceutical formulations according to claims 1-3 for the treatment of peripheral vasculopathies connected with impairments of the arterial or venous circles and of unesthetisms related to impaired capillary permeability and fragility, particularly for the treatment of superficial or deep scars; internal and external hemorrhoids; conditions related to chronic venous stasis, such as stasis ulcers and telangiectasias; couperose and peripheral capillaropathies.

5. Pharmaceutical and/or cosmetic formulations according to any one of the above claims, characterized in that they contain pure phospholipids or mixtures thereof as excipients.

6. The use of coumarins selected from esculoside, esculetin, extracts containing them and mixtures thereof, combined with dimeric and oligomeric proanthocyanidins, for the manufacturing of a medicament for topical use for the treatment of peripheral vasculopathies connected with impairments of the arterial or venous circles and of unesthetisms related to impaired capillary permeability and fragility; superficial or deep scars; internal and external hemorrhoids; conditions related to chronic venous stasis, stasis ulcers and telangiectasias; couperose and peripheral capillaropathies; atopic dermatitis and haematomas of any origin.
7. The use of coumarins selected from esculoside, esculetin, extracts containing them and mixtures thereof, for the manufacturing of a medicament for the topical use for the treatment of atopic dermatitis and haematomas of any origin.

Patentansprüche

1. Pharmazeutische und/oder kosmetische Formulierungen zur topischen Verwendung, die als Wirkstoffe
 - a) Cumarine, ausgewählt aus Aesculosid, Aesculetin, diese enthaltenden Extrakten und Gemischen davon, in Kombination mit
 - b) dimeren und oligomeren Proanthocyanidinen umfassen.
2. Pharmazeutische und/oder kosmetische Formulierungen nach Anspruch 1, dadurch gekennzeichnet, dass die enthaltenen Proanthocyanidine aus der Gruppe, bestehend aus Proanthocyanidin A2, Procyanidololigomeren extrahiert aus Vitis vinifera und Camellia sinensis, und Gemischen davon ausgewählt sind.
3. Pharmazeutische und/oder kosmetische Formulierungen nach Anspruch 2, dadurch gekennzeichnet, dass das enthaltene Proanthocyanidin Proanthocyanidin A2 ist.
4. Pharmazeutische Formulierungen nach den Ansprüchen 1 bis 3 zur Behandlung von peripheren Vaskulopathien mit Verschlechterungen der arteriellen oder venösen Kreisläufe und von unästhetischen Erscheinungsbildern im Zusammenhang mit verschlechterter Kapillarpermeabilität und -fragilität, insbesondere zur Behandlung oberflächlicher oder tiefer Narben, innerer oder äußerer Hämorrhoiden, von Zuständen im Zusammenhang mit chronischer Venostase wie Stauungslucera und Teleangiectasien, Cuperose und peripherer Kapillaropathien.
5. Pharmazeutische und/oder kosmetische Formulierungen nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass sie reine Phospholipide oder Gemische davon als Exzipienten enthalten.
6. Verwendung von Cumarinen, ausgewählt aus Aesculosid, Aesculetin, diese enthaltenden Extrakten und Gemischen davon, in Kombination mit dimeren und oligomeren Proanthocyanidinen zur Herstellung eines Medikaments zur topischen Verwendung zur Behandlung von peripheren Vaskulopathien mit Verschlechterungen der arteriellen oder venösen Kreisläufe und von unästhetischen Erscheinungsbildern im Zusammenhang mit verschlechterter Kapillarpermeabilität und -fragilität, oberflächlicher oder tiefer Narben, innerer oder äußerer Hämorrhoiden, von Zuständen im Zusammenhang mit chronischer Venostase, Stauungslucera und Teleangiectasien; Cuperose und peripherer Kapillaropathien, atopischer Dermatitis und Hämatomen beliebigen Ursprungs.
7. Verwendung von Cumarinen, ausgewählt aus Aesculosid, Aesculetin, diese enthaltenden Extrakten und Gemischen davon, zur Herstellung eines Medikaments zur topischen Verwendung zur Behandlung von atopischer Dermatitis und Hämatomen beliebigen Ursprungs.

Revendications

1. Formulations pharmaceutiques et/ou cosmétiques à usage topique, contenant, comme principes actifs :
 - a) des coumarines choisies parmi l'esculoside, l'esculéline, des extraits les contenant et leurs mélanges, en association avec
 - b) des proanthocyanidines dimères et oligomères.
2. Formulations pharmaceutiques et/ou cosmétiques selon la revendication 1, caractérisées en ce que les proantho-

cyanidines contenues sont choisies dans le groupe formé par la proanthocyanidine A2, les oligomères procyanidoliques extraits de *vitis vinifera* et *Camellia sinensis*, et leurs mélanges.

3. Formulations pharmaceutiques et/ou cosmétiques selon la revendication 2, caractérisées en ce que la proanthocyanidine contenue est la proanthocyanidine A2.
4. Formulations pharmaceutiques selon les revendications 1 à 3 pour le traitement de vasculopathies périphériques liées à des altérations des cercles artériels ou veineux et de défauts esthétiques liés à une perméabilité capillaire altérée et une fragilité capillaire, en particulier pour le traitement de cicatrices superficielles ou profondes ; d'hémorroïdes internes et externes ; d'affections liées à une stase veineuse chronique, tels que les ulcères de stase et les télangiectasies ; de couperose et de capillaropathies périphériques.
5. Formulations pharmaceutiques et/ou cosmétiques selon l'une quelconque des revendications précédentes, caractérisées en ce qu'elles contiennent des phospholipides purs ou des mélanges d'entre eux comme excipients.
6. L'utilisation de coumarines choisies parmi l'esculoside, l'esculétine, des extraits les contenant et leurs mélanges, en association avec des proanthocyanidines dimères et oligomères, pour la fabrication d'un médicament à usage topique pour le traitement de vasculopathies périphériques liées à des altérations des cercles artériels ou veineux et de défauts esthétiques liés à une perméabilité capillaire altérée et une fragilité capillaire ; de cicatrices superficielles ou profondes ; d'hémorroïdes internes et externes ; d'affections liées à une stase veineuse chronique, d'ulcères de stase et de télangiectasies ; de couperose et de capillaropathies périphériques ; d'eczéma atopique et d'hématomes de n'importe quelle origine.
7. L'utilisation de coumarines choisies parmi l'esculoside, l'esculétine, des extraits les contenant et leurs mélanges, pour la fabrication d'un médicament à usage topique pour le traitement d'eczéma atopique et d'hématomes de n'importe quelle origine.